ART 6043
Alternative Names: ART-6043Latest Information Update: 01 Jul 2025
At a glance
- Originator Artios Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA polymerase theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Solid tumours at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 23 Oct 2024 Safety and pharmacodynamics data from a preclinical studies in Solid tumours presented at the (full name of conference 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR - 2024)
- 30 Jun 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT05898399)